Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102267 · ClinicalTrials.gov registry record · Phase 4
Extended Delivery of Bupivacaine Study in Herniorrhaphy
A Phase 4 study, sponsored by Heron Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT04102267 is a Phase 4 study that has completed, run by Heron Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT04102267, a Phase 4 study, has completed, sponsored by Heron Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase 4, randomized, open-label study of the efficacy, safety, and pharmacokinetics of bupivacaine administered as liposomal bupivacaine or continuous infusion via elastomeric pump following unilateral open inguinal herniorrhaphy.
Interventions
- DRUG Bupivacaine liposome injectable suspension
- DRUG Bupivacaine HCl without epinephrine via continuous infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-07-02 |
| Est. Completion | 2018-10-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04102267
The ClinicalTrials.gov registry entry for NCT04102267 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heron Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine liposome injectable suspension is the first listed.
NCT04102267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04102267 about?
NCT04102267 is a clinical study titled "Extended Delivery of Bupivacaine Study in Herniorrhaphy". This is a phase 4, randomized, open-label study of the efficacy, safety, and pharmacokinetics of bupivacaine administered as liposomal bupivacaine or continuous infusion via elastomeric pump following unilateral open inguinal herniorrhaphy.
What is the current status of trial NCT04102267?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2018-07-02. Estimated completion is 2018-10-26.
What interventions are being tested in trial NCT04102267?
The interventions under investigation include: Bupivacaine liposome injectable suspension (DRUG), Bupivacaine HCl without epinephrine via continuous infusion (DRUG).
Who is sponsoring clinical trial NCT04102267?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.